Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Absorption Systems Awarded Third CellPort Patent | Contract Pharma

What are you searching for?

Sign in
Breaking News

Absorption Systems Awarded Third CellPort Patent

Extends patent coverage on transporter knockdown technology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Absorption Systems was issued a third U.S. patent for its CellPort Technologies portfolio of in vitro test systems. The new patent covers its MRP2 knockdown cell line and extends the patent coverage on the transporter knockdown technology beyond previously issued patents in the U.S., Europe, and Panama. The cell-based test systems are designed to allow drug developers to definitively predict the risk of clinical drug-drug interactions (DDIs) involving drug transporters.
 
The newly patented in vitro test systems were developed by Absorption Systems’ chief scientist, Dr. Ismael Hidalgo, who leads the company’s preclinical R&D, including collaborations with academic, industrial, and FDA scientists. Dr. Hidalgo said, “This patent further validates our commitment to develop better tools that predict clinical outcomes, improve drug safety, and save lives. CellPort Technologies can provide very definitive data on drug transporters, which is now required by regulatory agencies such as the FDA. And the technology is exclusive to Absorption Systems.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters